Screener
NeoGenomics NEO G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| COST OF REVENUE | 109,778 | 104,072 | 215,586 | 198,861 |
| GROSS PROFIT | 91,878 | 77,258 | 172,742 | 150,504 |
| Operating expenses: | ||||
| General and administrative | 63,613 | 71,747 | 129,354 | 139,954 |
| Research and development | 10,761 | 9,023 | 20,295 | 19,204 |
| Sales and marketing | 27,275 | 24,075 | 51,105 | 46,758 |
| Impairment charges (Note 5) | — | 20,041 | — | 20,041 |
| Total operating expenses | 101,649 | 124,886 | 200,754 | 225,957 |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's G&A?
- NeoGenomics (NEO) reported G&A of $63.61M in Q2 2026.
- How has NeoGenomics's G&A changed year-over-year?
- NeoGenomics's G&A decreased by 11.3% year-over-year, from $71.75M to $63.61M.
- What is the long-term trend for NeoGenomics's G&A?
- Over 4 years (2021 to 2025), NeoGenomics's G&A has grown at a 5.4% compound annual growth rate (CAGR), from $221.35M to $273.34M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about NeoGenomics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude